Lorazepam
Castration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLCSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Castration-Resistant Prostatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benadryl Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
Ifinatamab Deruxtecan Merck Sharp & Dohme LLC | Phase 1/2 | CC |
mk-5684 Merck Sharp & Dohme LLC | Phase 1/2 | CC |
Vobramitamab Duocarmazine MacroGenics | Phase 2 | CC |
CC-1 University Hospital Tuebingen | Phase 1 | CC |
cc-1, psmaxcd3 University Hospital Tuebingen | Phase 1 | CC |
111in-dota-h11b6 SpectronRX | Early Phase 1 | C |
lutetium (<sup>177</sup>Lu) zadavotide guraxetan | D |
Same molecule, other indications
Lorazepam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →